Institutional Backing and Strong Fundamentals Bolster Masimo Amid Apple Patent Dispute

While its high-profile legal battle with Apple Inc. continues to generate headlines, medical technology firm Masimo is simultaneously drawing significant confidence from major financial institutions. Recent substantial investments from heavyweight funds and a solid quarterly earnings report suggest strong underlying faith in the company’s long-term prospects, despite ongoing patent litigation.

Major Funds Amplify Their Stakes

In a powerful show of conviction, several institutional investors have significantly increased their holdings in Masimo. The most notable move came from Durable Capital Partners, which purchased additional shares valued at $187.5 million. This substantial investment is a clear endorsement of the company’s strategic direction and future potential.

This sentiment was echoed by other prominent funds, including Bridger Management, 4D Advisors, and Price T Rowe Associates, which also expanded their positions. These decisive actions by sophisticated market participants indicate a belief that the company’s fundamental business strength outweighs the near-term uncertainties presented by its legal challenges.

Financial Performance Exceeds Expectations

Masimo’s operational resilience was on full display in its latest quarterly results. The company reported earnings per share (EPS) of $1.33, surpassing analyst forecasts. Revenue climbed to $370.9 million, representing a robust 7.7% year-over-year increase. This growth is particularly impressive given the resources being allocated to the complex legal dispute.

A key forward-looking metric also showed strength. The book-to-bill ratio, an indicator of future sales, increased by 7%. From this growing contract portfolio, Masimo anticipates approximately $490 million in revenue for the coming year, which would mark an 18% improvement over the prior year.

Should investors sell immediately? Or is it worth buying Masimo?

The Core of the Legal Challenge with Apple

The dispute centers on patented technology for measuring blood oxygen levels in smartwatches. The conflict has entered a new phase as U.S. Customs authorities have moved to dismiss a related legal proceeding from Masimo. The authorities contend that the U.S. International Trade Commission (ITC), not the courts, holds jurisdiction over the matter.

Masimo alleges that Apple is circumventing an import ban on certain Watch models by using a software update to disable the contested feature. Should the court side with Customs, the patent infringement battle, which began in 2023, will be further prolonged, creating continued uncertainty for Masimo in the lucrative wearable technology market.

A Clear Path for Market Expansion

Beyond the litigation, Masimo’s growth strategy remains focused. Management recently outlined its plans at the Wells Fargo Healthcare Conference. While the overall pulse oximetry market is expanding at a steady annual rate of about 3%, Masimo is consistently capturing an additional 1-2 percentage points of market share each year.

The company identifies particularly significant potential in the advanced monitoring segment, where current market penetration remains below 20%. This area represents a substantial opportunity for future profitable expansion. The critical question remains whether Masimo can successfully navigate its legal hurdles and fully capitalize on its technological leadership to drive sustained growth—a prospect that major investors appear to believe in strongly.